Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101
Solid Biosciences Inc. (SLDB)
Last solid biosciences inc. earnings: 8/14 07:25 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.solidbio.com/investor-relations
Company Research
Source: GlobeNewswire
- Non-exclusive license for Solid’s proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio’s gene therapy for dysferlin-related limb-girdle muscular dystrophy - - Solid to receive an upfront payment and is eligible for certain development and sales milestones and tiered royalties on net sales -- Solid continues to expand collaborative efforts for AAV-SLB101 with more than 25 agreements and licenses executed to date - CHARLESTOWN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non-exclusive worldwide license and collaboration agreement with Kinea Bio for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101, for the development and commercialization of KNA-155, an investigational dual AAV gene therapy targeting dysferlinopathy, a form of limb-girdle muscular
Show less
Read more
Impact Snapshot
Event Time:
SLDB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLDB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLDB alerts
High impacting Solid Biosciences Inc. news events
Weekly update
A roundup of the hottest topics
SLDB
News
- Solid Biosciences (NASDAQ:SLDB) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.MarketBeat
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s AtaxiaGlobeNewswire
- Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 [Yahoo! Finance]Yahoo! Finance
- Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101GlobeNewswire
SLDB
Earnings
- 11/3/25 - Miss
SLDB
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- 12/4/25 - Form 4
- SLDB's page on the SEC website